Stemline Therapeutics News

Investor demand for shares of Stemline Therapeutics seems to be picking up tremendously, as the stock rallied 13.3% higher yesterday to reach a new high of $16.49 per share in yesterday's trading .

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! NEW YORK, April 25, 2013 -- Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells and tumor bulk, reported today its year-end 2012 financial results.

The firm set a "buy" rating and a $35.00 price target on the stock. The analysts wrote, "In our view, Stemline Therapeutics represents a unique investment opportunity in the small-cap oncology arena, due to its proprietary knowledge base in the domain of cancer stem cells , its rapidly advancing clinical-stage pipeline, and its extremely ... (more)

Stemline Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells and tumor bulk, announced today that Ivan Bergstein, M.D., Chief Executive Officer, will present at the 25th Annual Roth Conference on Wednesday, March 20th, 2013 at 8:00AM PT.